Genfit readies its $120M IPO; Karyopharm shares boosted after an FDA delay for selinexor
→ Weeks after officially unveiling its plan to list on the Nasdaq, Lille-based liver drug developer Genfit on Thursday said it would offer 5 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
